ZEBA SAMI: Open Payments
NPI 1295889046 · ELM GROVE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,587 in 65 payments from 16 companies in 2025. Trend: 2023 $1,602 · 2024 $2,089 · 2025 $1,587
Food & beverage: $1,587
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $334 |
| ABBVIE INC. | 10 | $286 |
| Axsome Therapeutics, Inc. | 5 | $184 |
| Otsuka America Pharmaceutical, Inc. | 8 | $168 |
| Lundbeck LLC | 10 | $165 |
| Alkermes, Inc. | 10 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Auvelity, ARISTADA, TRINTELLIX, ABILIFY ASIMTUFII, FANAPT.
Industry payments across WI — which companies pay providers there.
